20190605 Transgene publi TG4001 TG6002 EN
Category: TG6002
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
20181017 PR TG6002 US
Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
180820 – TG Tasly Closing EN
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
180710 – TG Tasly agreement PR
TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation
First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
20171026-PR-TG6002
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al. Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article Publication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
